Lorie Johnson, the chief medical reporter for CBN News, interviewed Dr. Dale Bredesen as part of a panel of Alzheimer’s experts who weighed in on the FDA’s approval of Biogen’s drug Aduhelm.

The drug approved under an “accelerated approval” process has many in the medical community concerned about the lack of scientific data for its efficacy and how it is being rushed to market with significant risks and side effects such as brain swelling and bleeding.

Aduhelm is claimed to be able to remove amyloid plaque in the brain, but as Dr. Bredesen explains during the interview that removing amyloid doesn’t get rid of Alzheimer’s, nor does it address the causes and triggers for the disease.

Share This: